231 related articles for article (PubMed ID: 28082068)
1. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
Ren Q; Liu X; Luo Z; Li J; Wang C; Goldmann S; Zhang J; Zhang Y
Bioorg Med Chem; 2017 Feb; 25(3):1042-1056. PubMed ID: 28082068
[TBL] [Abstract][Full Text] [Related]
2. 3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4.
Ren Q; Liu X; Yan G; Nie B; Zou Z; Li J; Chen Y; Wei Y; Huang J; Luo Z; Gu B; Goldmann S; Zhang J; Zhang Y
J Med Chem; 2018 Feb; 61(3):1355-1374. PubMed ID: 29381358
[TBL] [Abstract][Full Text] [Related]
3. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations.
Wang XY; Wei ZM; Wu GY; Wang JH; Zhang YJ; Li J; Zhang HH; Xie XW; Wang X; Wang ZH; Wei L; Wang Y; Chen HS
Antivir Ther; 2012; 17(5):793-803. PubMed ID: 22668794
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors.
Ma Y; Zhao S; Ren Y; Cherukupalli S; Li Q; Woodson ME; Bradley DP; Tavis JE; Liu X; Zhan P
Eur J Med Chem; 2021 Dec; 225():113780. PubMed ID: 34438123
[TBL] [Abstract][Full Text] [Related]
5. Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein.
Wang J; Zhang H; Zhang Y; Jiang D; Li J; Goldmann S; Ren Q; Fei R; Wang X; Wei L
J Med Virol; 2017 Oct; 89(10):1804-1810. PubMed ID: 28401569
[TBL] [Abstract][Full Text] [Related]
6. A new series of HAPs as anti-HBV agents targeting at capsid assembly.
Yang XY; Xu XQ; Guan H; Wang LL; Wu Q; Zhao GM; Li S
Bioorg Med Chem Lett; 2014 Sep; 24(17):4247-9. PubMed ID: 25127104
[TBL] [Abstract][Full Text] [Related]
7. Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
Qiu Z; Lin X; Zhou M; Liu Y; Zhu W; Chen W; Zhang W; Guo L; Liu H; Wu G; Huang M; Jiang M; Xu Z; Zhou Z; Qin N; Ren S; Qiu H; Zhong S; Zhang Y; Zhang Y; Wu X; Shi L; Shen F; Mao Y; Zhou X; Yang W; Wu JZ; Yang G; Mayweg AV; Shen HC; Tang G
J Med Chem; 2016 Aug; 59(16):7651-66. PubMed ID: 27458651
[TBL] [Abstract][Full Text] [Related]
8. Optimization and Synthesis of Pyridazinone Derivatives as Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation.
Lu D; Liu F; Xing W; Tong X; Wang L; Wang Y; Zeng L; Feng C; Yang L; Zuo J; Hu Y
ACS Infect Dis; 2017 Mar; 3(3):199-205. PubMed ID: 27989113
[TBL] [Abstract][Full Text] [Related]
9. A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers.
Zhao N; Jia B; Zhao H; Xu J; Sheng X; Luo L; Huang Z; Wang X; Ren Q; Zhang Y; Zhao X; Cui Y
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636065
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors.
Boucle S; Lu X; Bassit L; Ozturk T; Russell OO; Amblard F; Coats SJ; Schinazi RF
Bioorg Med Chem Lett; 2017 Feb; 27(4):904-910. PubMed ID: 28094179
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.
Qiu Z; Lin X; Zhang W; Zhou M; Guo L; Kocer B; Wu G; Zhang Z; Liu H; Shi H; Kou B; Hu T; Hu Y; Huang M; Yan SF; Xu Z; Zhou Z; Qin N; Wang YF; Ren S; Qiu H; Zhang Y; Zhang Y; Wu X; Sun K; Zhong S; Xie J; Ottaviani G; Zhou Y; Zhu L; Tian X; Shi L; Shen F; Mao Y; Zhou X; Gao L; Young JAT; Wu JZ; Yang G; Mayweg AV; Shen HC; Tang G; Zhu W
J Med Chem; 2017 Apr; 60(8):3352-3371. PubMed ID: 28339215
[TBL] [Abstract][Full Text] [Related]
12. The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells.
Huber AD; Wolf JJ; Liu D; Gres AT; Tang J; Boschert KN; Puray-Chavez MN; Pineda DL; Laughlin TG; Coonrod EM; Yang Q; Ji J; Kirby KA; Wang Z; Sarafianos SG
mSphere; 2018 Apr; 3(2):. PubMed ID: 29669885
[TBL] [Abstract][Full Text] [Related]
13. Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors.
Jia H; Yu J; Du X; Cherukupalli S; Zhan P; Liu X
Eur J Med Chem; 2020 Sep; 202():112495. PubMed ID: 32712535
[TBL] [Abstract][Full Text] [Related]
14. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly.
Wu G; Liu B; Zhang Y; Li J; Arzumanyan A; Clayton MM; Schinazi RF; Wang Z; Goldmann S; Ren Q; Zhang F; Feitelson MA
Antimicrob Agents Chemother; 2013 Nov; 57(11):5344-54. PubMed ID: 23959305
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of aminothiazole based Hepatitis B Virus (HBV) capsid inhibitors.
Pan T; Ding Y; Wu L; Liang L; He X; Li Q; Bai C; Zhang H
Eur J Med Chem; 2019 Mar; 166():480-501. PubMed ID: 30739828
[TBL] [Abstract][Full Text] [Related]
16. A New Role for Capsid Assembly Modulators To Target Mature Hepatitis B Virus Capsids and Prevent Virus Infection.
Ko C; Bester R; Zhou X; Xu Z; Blossey C; Sacherl J; Vondran FWR; Gao L; Protzer U
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658963
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly.
Wu S; Zhao Q; Zhang P; Kulp J; Hu L; Hwang N; Zhang J; Block TM; Xu X; Du Y; Chang J; Guo JT
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566379
[TBL] [Abstract][Full Text] [Related]
19. Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1.
Bourne CR; Finn MG; Zlotnick A
J Virol; 2006 Nov; 80(22):11055-61. PubMed ID: 16943288
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays.
Wang Y; Wang Z; Liu J; Wang Y; Wu R; Sheng R; Hou T
Bioorg Med Chem; 2021 Apr; 36():116096. PubMed ID: 33721800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
